NASDAQ:ELOX - Eloxx Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.03
  • Forecasted Upside: 131.80 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.74
▲ +0.15 (9.43%)

This chart shows the closing price for ELOX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eloxx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELOX

Analyst Price Target is $4.03
▲ +131.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $4.03, with a high forecast of $5.00 and a low forecast of $3.10. The average price target represents a 131.80% upside from the last price of $1.74.

This chart shows the closing price for ELOX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Eloxx Pharmaceuticals. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/7/2021MizuhoReiterated RatingBuy$3.10High
6/29/2021MizuhoInitiated CoverageBuy$3.10Medium
5/27/2021B. RileyInitiated CoverageBuy$5.00Low
5/19/2021Piper SandlerLower Price TargetOverweight$6.00 ➝ $4.00Low
11/9/2020HC WainwrightReiterated RatingNeutralHigh
6/10/2020CitigroupDowngradeBuy ➝ Neutral$11.00 ➝ $4.00High
5/12/2020Canaccord GenuityReiterated RatingBuy$6.00High
5/8/2020Janney Montgomery ScottLower Price TargetBuy$13.00 ➝ $10.00High
5/8/2020Piper SandlerLower Price TargetOverweight$10.00 ➝ $6.00High
3/9/2020CitigroupLower Price TargetNeutral$31.00 ➝ $11.00High
3/6/2020Janney Montgomery ScottLower Price TargetBuy$14.00 ➝ $13.00N/A
3/6/2020Piper SandlerLower Price Target$14.00 ➝ $10.00N/A
3/6/2020HC WainwrightReiterated RatingNeutral$10.00 ➝ $3.00High
9/6/2019Janney Montgomery ScottInitiated CoverageBuy$14.00Low
8/8/2019SunTrust BanksLower Price TargetBuy$10.00Medium
5/15/2019Canaccord GenuityReiterated RatingBuy$20.00 ➝ $17.00Low
12/24/2018HC WainwrightReiterated RatingNeutralLow
12/24/2018HC WainwrightInitiated CoverageNeutral ➝ Neutral$10.00Low
7/3/2018CitigroupInitiated CoverageBuy$31.00Low
6/29/2018Canaccord GenuityInitiated CoverageBuy$24.00High
6/25/2018SunTrust BanksInitiated CoverageBuy$26.00Medium
5/1/2018Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Medium
(Data available from 9/16/2016 forward)

News Sentiment Rating

-0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/18/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/17/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/16/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Eloxx Pharmaceuticals logo
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $1.74
Low: $1.63
High: $1.81

50 Day Range

MA: $1.47
Low: $1.22
High: $1.74

52 Week Range

Now: $1.74
Low: $1.18
High: $6.77

Volume

37,609 shs

Average Volume

956,626 shs

Market Capitalization

$149.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Eloxx Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Eloxx Pharmaceuticals in the last year: B. Riley, HC Wainwright, Mizuho, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ELOX.

What is the current price target for Eloxx Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Eloxx Pharmaceuticals in the last year. Their average twelve-month price target is $4.03, suggesting a possible upside of 131.8%. B. Riley has the highest price target set, predicting ELOX will reach $5.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $3.10 for Eloxx Pharmaceuticals in the next year.
View the latest price targets for ELOX.

What is the current consensus analyst rating for Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELOX will outperform the market and that investors should add to their positions of Eloxx Pharmaceuticals.
View the latest ratings for ELOX.

What other companies compete with Eloxx Pharmaceuticals?

How do I contact Eloxx Pharmaceuticals' investor relations team?

Eloxx Pharmaceuticals' physical mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company's listed phone number is (781) 577-5300 and its investor relations email address is [email protected] The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com.